[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kasr El Aini Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":617},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,45,67,79,102,128,151,178,202,229,250,278,308,337,362,390,414,443,463,484,508,532,554,575,595],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054207","the-analgesic-efficacy-of-dexmedetomidine-versus-fentanyl-as-an-adjuvant-to-bupivacaine-in-ultrasound-guided-peripheral-nerve-blocks-as-a-solo-anesthetic-technique-in-high-risk-patients-undergoing-unilateral-above-knee-amputation--100054207",false,"NCT07640516","The Analgesic Efficacy of Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Ultrasound Guided Peripheral Nerve Blocks as a Solo Anesthetic Technique in High Risk Patients Undergoing Unilateral Above Knee Amputation .","The Analgesic Efficacy of Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Ultrasound Guided Peripheral Nerve Blocks as a Solo Anesthetic Technique in High Risk Patients Undergoing Unilateral Above Knee Amputation : A Randomized Double Blinded Study","Inclusion Criteria:\n\n* \\- Age ≥18 years\n* Both sexes\n* ASA III-IV\n* Documented cardiac disease (e.g., EF \\\u003C 40%, NYHA II or higher)\n* Documented pulmonary disease (e.g., COPD with FEV1 \\\u003C 60%)\n* Scheduled for above-knee amputations\n\nExclusion Criteria:\n\n* Neurological or intellectual disability\n* Drug abuse\n* Allergy to study drugs\n* Pregnancy\n* Contraindications to regional anesthesia (e.g., coagulopathy, local infection)\n* Significant renal or hepatic impairment( plts \\\u003C75000 or INR \\>1.5)\n* Current anticoagulant therapy\n* severe haemodynamically unstability at the time of block performance, defined as map \\> 65 mmhg but achieved by high-dose vasopressors (e.g., norepinephrine ≥ 0.1 mcg\u002Fkg\u002Fmin) after fluid ressuscitation .","ALL","18 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to compare the analgesic efficacy and safety of dexmedetomidine versus fentanyl as adjuvants to bupivacaine in ultrasound-guided combined supra-inguinal fascia iliaca and proximal sciatic nerve blocks used as a solo anesthetic technique in high-risk patients undergoing unilateral above knee amputation.",[27,28,29],"Analgesia Assessment","Above Knee Amputation","Fentanyl vs Dexmedetomidine",[31],"dexmedetomidine vs fentanyl PNBs AKA","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":21},"2026-07-01",{"date":40,"type":21},"2027-03-01",{"name":42,"class":43},"Kasr El Aini Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100642100","dexmedetomidine-as-an-adjuvant-to-bupivacaine-in-ultrasound-guided-pericapsular-nerve-group-block-peng-100642100","NCT07626346","Dexmedetomidine as an Adjuvant to Bupivacaine in Ultrasound-guided Pericapsular Nerve Group Block( PENG)","The Analgesic Efficacy of Dexmedetomidine as an Adjuvant to Bupivacaine in Ultrasound-guided Pericapsular Nerve Group Block( PENG) in Patients Undergoing Laparoscopic Shoulder Surgeries: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Male or female patients aged 18-65 years\n2. Patients Undergoing laparoscopic shoulder surgeries (shoulder arthroplasties and shoulder endoscopic surgeries )\n3. American Society of Anesthesiologists (ASA) physical status I-II\n\nExclusion Criteria:\n\n1. Patient refusal.\n2. hypersensitivity or contraindication to dexmedetomidine\n3. History of allergy or intolerance to study medications\n4. Chronic opioid use (\\>3 months)\n5. Pregnancy or breastfeeding\n6. Severe renal or hepatic impairment\n7. Patient's with coagulopathy disorders",true,"65 Years",{"count":55,"type":21},84,[24],"Patients are greatly concerned about pain that occurs shortly after shoulder surgeries. Most patients experience significant pain after shoulder surgery, with almost half reporting severe pain immediately after. Since shoulder surgeries are usually done as outpatient or one day procedures, good pain control after surgery is important for quick recovery and rehab for patient's overall recovery. Interscalene nerve blocks provide the best pain relief for shoulder surgery patients. They reduce pain for at least 8 hours and decrease the need for opioids for 8 to 12 hours after surgery. It anesthetizes most of the brachial plexus, except the ulnar nerve (C8-T1). It is useful for surgeries on the distal clavicle, shoulder, and proximal humorous .However, interscalene blocks also raise concerns about temporary and potential long-term problems with breathing, especially paralysis of the diaphragm and phrenic nerve. By targeting nerve roots in the neck rather than peripheral nerves, interscalene blocks also carry a higher risk of nerve damage.The pericapsular nerve group block has been effectively used in hip surgeries as in hip arthroplasty and it is one of the best regional anesthesia regarding many other hip operations. Recently PENG block has also shown to have strong analgesic effect on shoulder surgeries.\n\nDexmedetomidine (DEX) is a highly selective Alpha-2 adrenergic agonist. It has sedative and analgesic properties that thought to be due to binding to both presynaptic and postsynaptic alpha-2 adrenoreceptors and inhibiting the release of norepinephrine, as a result, it terminates the propagation of pain signals and inhibits the sympathetic activity decreasing heart rate and blood pressure.\n\nThe aim of our study is to compare the effect of adding dexmedetomidine to bupivacaine in ultrasound-guided Pericapsular nerve group block (PENG) with bupivacaine alone and determine its effect on duration of analgesia and post-operative opioid consumption.",[59],"Shoulder Pain","2026-06-10",{"date":62,"type":36},"2026-06-12",{"date":60,"type":36},{"date":65,"type":21},"2026-11",{"name":42,"class":43},{"id":68,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":25,"conditions":71,"keywords":72,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":78,"locationsCount":44},"100643114",{"count":20,"type":21},[24],[27,28,29],[31],"NOT_YET_RECRUITING","2026-06-06",{"date":60,"type":36},{"date":38,"type":21},{"date":40,"type":21},{"name":42,"class":43},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100643773","phase-4-the-effect-of-doxapram-on-diaphragmatic-excursionde-during-weaning-from-mechanical-ventilation-100643773","NCT07637149","the Effect of Doxapram on Diaphragmatic Excursion(DE) During Weaning From Mechanical Ventilation.","the Effect of Doxapram on Diaphragmatic Excursion(DE) During Weaning From Mechanical Ventilation :a Randomized Double Blinded Study.","Inclusion Criteria:\n\n* Adults (≥18 years) on mechanical ventilation for \\>48 hours.\n* Deemed ready for weaning by the clinical team: Defined as RSBI \\\u003C105, P\u002FF ratio \\>200, hemodynamic stability.\n* Stable hemodynamics and adequate oxygenation (PaO₂\u002FFiO₂ \\>150)\n\nExclusion Criteria:\n\n* Severe neurological impairment :Defined as GCS ≤8 or spinal cord injury above T5 .\n\n  * Known hypersensitivity to doxapram.\n  * Pregnancy or lactation.",{"count":87,"type":21},60,[89],"PHASE4","The goal of this clincal trial is to learn if doxapram is effective in weaning in adults on mechanical ventilation.\n\nThe objectives of this study:\n\n* Evaluate the effect of doxapram on diaphragmatic function (assessed by DE)during weaning from mechanical ventilation.\n* Assess the impact of doxapram on respiratory muscle sterngth.\n* Mointor adverse effects associated with doxapram administration.\n\nResearchers will compare expermental group(intervenous doxapram during weaning)with control group(saline infusion)during weaning.\n\nThe patients who fulfull criteria of weaning will be subjected to our clincal trial and put on spontanous breathing trial for 120mins using positive end expiratory pressure (peep)5 cmh2o,pressure support 5cm h2o and fio2 0.3.By the end of the SBTthe patient will be extubated if ventilator parameters and vital signs were maintained within 20%of baseline values.\n\nThe patients will be followed up after extubation and afailed weaning will be defined as the neeed for either invasive or non invasive ventilation for 72 after extubation or failed SBT.",[92,93],"Mechanically Ventilated ICU Patients","Diaphragm Excursion","2026-06-05",{"date":96,"type":36},"2026-06-09",{"date":98,"type":21},"2026-06-01",{"date":100,"type":21},"2027-01-01",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":52,"sex":109,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":127,"locationsCount":44},"100636234","jak2-expression-in-androgenetic-alopecia-before-and-after-topical-minoxidil-100636234","NCT07563036","JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil","Assessment of Janus Kinase 2 Expression in Patients With Androgenic Alopecia and Its Modulation by Topical Minoxidil Therapy.","Inclusion Criteria:\n\n* Male adults aged 18 to 50 years with androgenetic alopecia.\n* Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.\n* Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Other types of hair loss, including inflammatory or scarring alopecia.\n* Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.\n* Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.\n* History of severe systemic disease, including renal, cardiovascular, or hepatic disease.\n* Chemotherapy during the last 5 years.\n* Bleeding disorders.","MALE","50 Years",{"count":7,"type":21},[24],"Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.",[115,116],"Androgenetic Alopecia","Androgenic Alopecia",[116,118,119,120],"Janus Kinase 2","JAK2","minoxidil","2026-04-25",{"date":123,"type":36},"2026-05-01",{"date":125,"type":36},"2026-02-01",{"date":100,"type":21},{"name":42,"class":43},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":44},"100634515","the-analgesic-efficacy-of-m-tapa-for-laparoscopic-abdominal-surgery-in-children-100634515","NCT07540689","The Analgesic Efficacy of M-TAPA for Laparoscopic Abdominal Surgery in Children","The Analgesic Efficacy of Modified Thoracoabdominal Nerve Block Through Perichondrial Approach for Laparoscopic Abdominal Surgery in Children: Randomized Controlled Trial","M-TAPA","Inclusion Criteria:\n\n* Age (1-7) years.\n* Both genders.\n* American Society of Anaesthesiologists (ASA) - physical status I-II.\n* Children undergoing elective laparoscopic abdominal surgery.\n\nExclusion Criteria:\n\n* Parental refusal.\n* Bleeding disorders with INR \\> 1.5 and\u002For platelets \\\u003C 50 000.\n* History of allergic reactions to local anesthetics.\n* Rash or signs of infection at the injection site.","1 Year","7 Years",{"count":87,"type":21},[24],"This investigation aims to assess the efficacy of M-TAPA in children undergoing laparoscopic abdominal surgery.\n\nSixty pediatric patients undergoing laparoscopic abdominal surgery under general anesthesia will be enrolled in this single-center study. Preoperatively, participants will be randomly assigned to receive either port-site local anesthetic infiltration or M-TAPA.",[142],"Post Operative Pain","2026-04-20",{"date":145,"type":36},"2026-04-23",{"date":147,"type":21},"2026-05",{"date":149,"type":21},"2027-04",{"name":42,"class":43},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":158,"minAge":18,"maxAge":110,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":44},"100634516","injectable-platelet-rich-fibrin-versus-intradermal-tranexamic-acid-for-melasma-100634516","NCT07540702","Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma","Assessment of Efficacy and Safety of Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid in the Treatment of Melasma: A Randomized Split-Face Study","Inclusion Criteria:\n\n* Clinical diagnosis of bilateral symmetrical facial melasma (epidermal or mixed type)\n* Female participants aged 18 to 50 years\n* Fitzpatrick skin types III to IV\n* Mild to moderate facial melasma\n* No melasma-specific treatment within the previous 4 weeks\n* No facial procedures, including peeling, laser resurfacing, or microneedling, within the previous 3 months\n* Willing and able to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Bleeding or coagulation disorders\n* Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or hormonal contraception\n* Active skin infection or facial inflammation\n* History of keloids or Koebner-prone conditions, such as psoriasis or vitiligo\n* Uncontrolled systemic disease, such as diabetes mellitus or autoimmune disease","FEMALE",{"count":160,"type":21},21,[24],"Melasma is a chronic acquired hyperpigmentation disorder that commonly affects the face and has a significant impact on quality of life. Available treatments may improve pigmentation, but relapse is common and response can be variable.\n\nThis randomized split-face interventional study aims to compare the efficacy and safety of injectable platelet-rich fibrin (i-PRF) versus intradermal tranexamic acid (TA) in the treatment of facial melasma. Adult female patients with bilateral symmetrical facial melasma will be enrolled. In each participant, one side of the face will be randomly assigned to receive i-PRF and the contralateral side will receive intradermal TA.\n\nPatients will undergo five treatment sessions at 2-week intervals. Clinical response will be assessed using the modified Melasma Area and Severity Index (mMASI), Antera 3D camera measurements, Physician Global Assessment, patient satisfaction, and Melasma Quality of Life (MelasQoL) questionnaire. Safety will be evaluated by recording adverse events such as pain, tenderness, erythema, swelling, infection, ecchymosis, and hematoma.\n\nThe study is designed to determine whether i-PRF is an effective and safe treatment option for melasma compared with intradermal tranexamic acid.",[164,165],"Melasma","Facial Melasma",[167,168,169,164,170],"Injectable platelet-rich fibrin","i-PRF","Tranexamic acid","Split-face study","2026-04-18",{"date":173,"type":36},"2026-04-22",{"date":125,"type":36},{"date":176,"type":21},"2026-10-01",{"name":42,"class":43},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100634166","phase-4-antihistamine-for-prevention-of-htr-after-blood-primed-cpb-100634166","NCT07536152","Antihistamine for Prevention of HTR After Blood Primed CPB","Prophylactic Antihistamine for Prevention of Hypotensive Transfusion Reaction After Blood Primed Cardiopulmonary Bypass in Pediatric Cardiac Surgery: a Randomized-controlled Study","HTR - CPB","Inclusion Criteria:\n\n* Acyanotic congenital heart disease.\n* Age :1 -7 years.\n* Genre: both.\n\nExclusion Criteria:\n\n* Redo patient.\n* History of allergy to antihistamines.\n* Bleeding disorders with INR \\> 1.5 and\u002For platelets \\\u003C 50,000.\n* Emergency procedure.",{"count":187,"type":21},40,[89],"This study will be a randomized, double-blinded, placebo-controlled study conducted at a university hospital. Forty children undergoing elective repair of a congenital heart defect will be included. The patients will be randomly allocated (20 patients per group) to receive a single intravenous dose of combined chlorpheniramine or normal saline immediately after separation from CPB, before protamine administration.",[191],"Blood Transfusion Associated Adverse Reactions",[193],"prevention of hypotensive transfusion reaction","2026-04-16",{"date":196,"type":36},"2026-04-21",{"date":198,"type":36},"2026-03-01",{"date":200,"type":21},"2026-12",{"name":42,"class":43},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":44},"100631614","topical-2-deoxy-d-ribose-hydrogel-versus-minoxidil-5-solution-for-androgenetic-alopecia-100631614","NCT07502976","Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia","Efficacy & Safety of Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution in Treatment of Androgenetic Alopecia: A Clinical & Biochemical Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to 50 years.\n* Male and female patients with androgenetic alopecia.\n* Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V in males and Ludwig scale I to II in females.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Other types of hair loss, including inflammatory or scarring alopecia.\n* Psoriasis.\n* Inflammatory scalp dermatoses.\n* History of severe systemic disease, including renal, cardiovascular, or hepatic disease.\n* Chemotherapy during the last 5 years.\n* Pregnancy.\n* Lactation.\n* Bleeding disorders.",{"count":87,"type":21},[24],"Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical minoxidil 5% solution in the treatment of mild to moderate androgenetic alopecia in adults aged 18 to 50 years. Sixty participants will be randomized into 2 treatment groups. The 2dDR group will apply 1 gram of topical 2dDR hydrogel once daily to the affected scalp areas for 6 months. The minoxidil group will apply topical minoxidil 5% solution to the affected scalp areas for 6 months according to sex-specific dosing in the protocol.\n\nParticipants will undergo clinical assessment, trichoscopic evaluation, and standardized scalp photography at baseline, Week 12, and Week 24. The study will also assess tissue vascular endothelial growth factor (VEGF) levels using scalp biopsy specimens obtained at baseline and after 3 months of treatment in both groups. Safety will be evaluated through adverse event monitoring and clinical scalp examination during follow-up visits.",[116],[214,215,216,217,218,219,220],"Male Pattern Hair Loss","Female Pattern Hair Loss","2-Deoxy-D-ribose","2dDR Hydrogel","Hair Loss","Trichoscopy","VEGF","2026-03-31",{"date":223,"type":36},"2026-04-06",{"date":225,"type":36},"2026-01-01",{"date":227,"type":21},"2027-01",{"name":42,"class":43},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":17,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":249,"locationsCount":44},"100630466","labroplasty-in-cases-of-anterior-shoulder-instability-with-subcritical-glenoid-bone-loss-100630466","NCT07488039","Labroplasty in Cases of Anterior Shoulder Instability With Subcritical Glenoid Bone Loss","Inclusion Criteria:\n\n* patients with recurrent anterior shoulder instability with one or more events of anterior shoulder dislocation.\n* Franceschi types 2 and 3 labral defects\n* subcritical glenoid bone loss \\\u003C20%\n* positive anterior shoulder apprehension\n\nExclusion Criteria:\n\n* Critical glenoid bones loss \\>20%\n* Franceschi type 1 labral defect\n* concomitant long head of biceps tendon pathology\n* multidirectional instability\n* prior arthroscopic shoulder stabilization surgery\n* concomitant proximal humeral fractures\n* concomitant Rotator cuff tears\n* skeletally immature patients\n* glenoid pathology\n* Shoulder arthritis\n* active infection","16 Years",{"count":160,"type":21},[24],"The goal of this clinical trial is to learn Labroplasty using the long head of biceps tendon works to patients with recurrent anterior shoulder instability with subcritical glenoid bone loss (\\\u003C20%) and thinned or deficient anterior labrum .The main questions it aims to answer are:\n\nDoes Labroplasty using the long head of biceps improve the functional and radiological outcomes in patients with recurrent anterior shoulder instability with subcritical glenoid bone loss?\n\nParticipants will:\n\nundergo arthroscopic labroplasty using the long head of biceps tendon Visit the clinic regularly for checkup and followup undergo MRI at 6 months to check radiological outcome",[240],"Recurrent Anterior Shoulder Instability",[242],"Labroplasty","2026-03-17",{"date":245,"type":36},"2026-03-23",{"date":225,"type":36},{"date":248,"type":21},"2027-12-31",{"name":42,"class":43},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":44},"100625808","phase-4-dexmedetomidine-midazolam-vs-ketamine-midazolam-on-emergence-delirium-100625808","NCT07427446","Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium","Prophylactic Effect of Dexmedetomidine-midazolam Versus Ketamine-midazolam on Emergence Delirium After Sevoflurane Anesthesia in Pediatric Cardiac Catheterization: A Randomized Controlled Study.","Inclusion Criteria:\n\n* Scheduled for elective cardiac catheterization under general anesthesia.\n\nExclusion Criteria:\n\n* neurological disorder, psychiatric disease, or current psychoactive medication.\n* allergy.\n* significant systemic comorbidities.","2 Years","6 Years",{"count":260,"type":21},50,[89],"Fifty children undergoing heart catheterization without local anesthesia in the skin will be randomly divided into two groups.\n\nGroup DM (Dexmedetomidine + Midazolam) and Group KM (Ketamine + Midazolam)",[264],"Emergence Delirium",[266,267,268,269,270],"Emergence delirium","Dexmedetomidine","Ketamine","Midazolam","sevoflurane","2026-02-24",{"date":273,"type":36},"2026-02-27",{"date":125,"type":36},{"date":276,"type":21},"2027-03",{"name":42,"class":43},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":285,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":44},"100626670","effect-of-mediterranean-vs-paleolithic-diet-on-ra-activity-sarcopenia-and-qol-12-week-rct-100626670","NCT07438652","Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCT","Effect of Mediterranean and Paleolithic Dietary Interventions on Nutritional Status, Disease Activity, Sarcopenia, and Quality of Life in Adults With Rheumatoid Arthritis: A 12-Week Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients classified as having rheumatoid arthritis according to the 2010 rheumatoid arthritis ACR\u002F EULAR classification criteria with a selected age group of 40 to 60 years old.\n\nExclusion Criteria:\n\n* Patients with comorbidities (e.g., diabetes mellitus, hypertension, gout, thyroid dysfunction).","40 Years","60 Years",{"count":288,"type":21},75,[24],"This study aims to evaluate the effects of Mediterranean and Paleolithic dietary interventions on nutritional status, disease activity, fatigue, sleep, and quality of life in adults with rheumatoid arthritis (RA). Participants aged 40-60 years will be randomly assigned to follow either a Mediterranean diet, a Paleolithic diet, or continue their usual diet for 12 weeks. The study will assess anthropometric measurements, disease activity score (DAS28), laboratory biomarkers (CBC, CRP, ESR, lipid profile, fasting glucose, HbA1c), and patient-reported outcomes. The trial will determine whether these diets improve RA management and overall well-being.",[292],"Rheumatoid Arthritis (RA)",[294,295,296,297,298,299,300],"Dietary Intervention","Rheumatoid arthritis","Paleolitic Diet","Mediterranean Diet","Sarcopenia","Quality of life","Nutrition","2026-02-22",{"date":273,"type":36},{"date":304,"type":36},"2026-01-17",{"date":306,"type":21},"2026-07-15",{"name":42,"class":43},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":158,"minAge":315,"maxAge":285,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":325,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":336,"locationsCount":44},"100624691","impact-tourniquet-conservative-placenta-accreta-neonatal-apgar-100624691","NCT07412925","Impact Tourniquet Conservative Placenta Accreta Neonatal APGAR","Impact of Using Tourniquet in Conservative Placenta Accrete Spectrum on Neonatal APGAR Score . A Randomized Controlled Trial .","Inclusion Criteria:\n\n1. Age: 20-40 years old.\n2. Pregnancy of a singleton living fetus.\n3. Gestational age: pregnancy completing 34 weeks or more.\n4. Previous one or more cesarean delivery.\n5. Current pregnancy complicated by Placena Accreta Spectrum Disorder candidate for conservative managment either total or partial Placenta Accreta.\n6. Elective termination of pregnancy. (35-37 weeks)\n7. Preoperative Hemoglobin ≥ 10 g\u002Fdl.\n\nExclusion Criteria:\n\n* 1-Patients who refuse to participate in the study. 2-Women with history of a concomitant chronic or a pregnancy associated medical disorder eg. Gestational diabetes, hypertension, cardiac or renal disease.\n\n  3-Presence of a concomitant uterine pathology (eg. Uterine fibroid) 4-Premature rupture of membranes. 5-Cases misdiagnosed as placenta accreta by ultrasound preoperatively, and spontaneous full placental separation occurred intraoperative or as total\u002Fpartial accreta and found to be focal accreta intraoperative.\n\n  6-Cases requiring preoperative blood transfusion. 7- Any fetal abnormality e.g IUGR or SGA","20 Years",{"count":317,"type":21},100,[24],"Placenta accreta spectrum disorder (PAS) refers to a condition where the placenta fails to separate naturally after childbirth, which can cause significant maternal and neonatal complications, including severe bleeding, leading to increased morbidity and mortality. According to the pathological characteristics, PAS can be classified into three categories, including placenta accreta, placenta increta, and placenta percreta. Risk factors for PAS were identified as cesarean section (CS), hysteroscopy history, in vitro fertilization and embryo transfer and placenta previa, etc. It was reported that over 90% of the PAS cases were with prior cesarean delivery. In order to reduce the morbidity and mortality caused by PAS, guidelines were released from several international societies, including the Federation of Gynecology and Obstetrics (FIGO), Royal College of Obstetricians and Gynecologists (RCOG), the American College of Obstetricians and Gynecologists (ACOG) and Society of Obstetricians and Gynecologists of Canada (SOGC) recommending comprehensive multidisciplinary team (MDT) and expertise in pelvic and abdominal surgeries are essential for patients with PAS. Antenatal diagnosis of PAS is highly advisable, which is closely associated with surgery options, bleeding management and success of uterine preservation. Current diagnostic approaches include imaging examination, PAS prenatal grading system and MDT. Severe complications of PAS (particularly in the case of PP), such as substantial hemorrhage and organ injury, are closely related to the placental position and trophoblast invasion depth. Ultrasonography and MRI are major imaging means for prenatal diagnosis. In the meantime, to preserve fertility, approaches to conservative surgical management for PAS have been developed. The purpose for conservative management of PAS patients is to reduce bleeding, avoid organ injury, preserve the uterus and maintain uterine function. As the concept of uterine preservation is accepted by more and more practitioners, conservative surgical techniques have been developed accordingly. According to the survey of the Society for Maternal-Foetal Medicine (SMFM), only 15-32% of doctors would apply conservative management for PAS cases. Due to the lack of high-quality clinical trials as well as follow-up studies, standardized surgical management for PAS has not yet been determined. There are three approaches applied to placenta management in PAS, including manual separation of placenta, one-step conservative surgery and leaving the placenta in situ. Removing the complete placenta can effectively reduce bleeding and infection and preserve the uterus. The classical \"Triple-P\" management was proposed in 2012, which includes perioperative placental localization, pelvic devascularization and placental non-separation with myometrial excision and uterine reconstruction. The uterine artery tourniquet has numerous advantages, including a decrease in blood loss and the number of transfused packed RBC units. The simplicity of the technique allows for residents to apply the tourniquet to decrease the bleeding and allows time until an experienced obstetrician arrives. Presently, other attempts to avoid hysterectomy include uterine compression sutures, intrauterine balloon tamponade, pelvic artery ligation, and spiral suturing of the lower uterine segment. Intrauterine balloon tamponade may increase CS scar dehiscence, uterine rupture, and infection. Best practices for these methods involve skilled surgeons and obstetricians who have detailed knowledge of pelvic artery anatomy that includes vascular variations or distortions. The Apgar score was established in 1953 as a rapid newborn assessment immediately after birth. It provides a mechanism to describe the situation of the fetus becoming a newborn. Physicians face many challenges in analyzing the fetus' transition into a baby in the delivery room, especially for premature ones. The Apgar score is usually used to analyze the newborn after birth in the delivery room briefly. Thus, the Apgar score analyzes the clinical signs in neonates, such as cyanosis, pallor, bradycardia, decreased reflex response to stimulation, hypotonia, and apnea, or breathing problems such as abnormal rate and tachypnea as quantitative data. The Apgar score is reported at 1 and 5 min after birth and repeated every 5 min up to 20 min for infants with an Apgar score \\\u003C7. A peculiar step of such a surgical approach involves the ligature of newly formed vessels between the uterus and the bladder. It has been speculated that such a step may affect the newborn by reducing blood flow to the placenta. This study aimed to report the neonatal outcome of women undergoing conservative reconstructive technique for PAS.",[321,322,323,324],"Pregnancy","Placenta Accrete Spectrum","Tourniquets","Apgar Score",[326,327,328,329],"placenta Accrete","Tourniquet","conservative","APGAR score","2026-02-09",{"date":332,"type":36},"2026-02-17",{"date":334,"type":36},"2025-04-30",{"date":198,"type":21},{"name":42,"class":43},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":361,"locationsCount":44},"100615276","gradual-versus-intermittent-release-of-tourniquet-effect-on-map-in-hypertensive-patients-undergoing-upper-limb-orthopedic-surgeries-100615276","NCT07290504","Gradual Versus Intermittent Release of Tourniquet Effect on MAP in Hypertensive Patients Undergoing Upper Limb Orthopedic Surgeries","The Effect of Gradual Versus Intermittent Release of Tourniquet on Mean Arterial Blood Pressure in Hypertensive Patients Undergoing Upper Limb Orthopedic Surgeries: A Blinded Randomized Controlled Study","Inclusion Criteria:\n\n* Hypertensive patients (controlled on medical treatment more than three months)\n* Patients scheduled for upper limb orthopedic surgeries using a tourniquet for at least 30 min.\n* BMI from 18.5 to 29.9\n\nExclusion Criteria:\n\n* Patient refusal\n* ASA physical status \\> II\n* Multiple orthopedic surgeries\n* Emergency surgeries\n* Patient with relative contraindications for tourniquet use",{"count":345,"type":21},68,[24],"In this clinical trial, the authors will compare two tourniquet deflation techniques and their clinical implications on hemodynamics and acid base parameters in hypertensive orthopedic patients undergoing upper limb surgeries under general anesthesia.",[349],"Hemodynamics",[351,352,327,353,354],"Mean arterial pressure","Acid base","Orthopedics","Hypertension","2025-12-17",{"date":357,"type":36},"2025-12-18",{"date":359,"type":36},"2025-12-13",{"date":147,"type":21},{"name":42,"class":43},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":44},"100607471","prilocaine-for-sphenopalatine-ganglion-block-in-endoscopic-hypophysectomy-100607471","NCT07188987","Prilocaine for Sphenopalatine Ganglion Block in Endoscopic Hypophysectomy","Bilateral Sphenopalatine Ganglion Block Using Prilocaine Versus Lidocaine as Adjuvants to General Anesthesia During Endoscopic Hypophysectomy, Randomized Trial.","Inclusion Criteria:\n\n* Patients with pituitary adenoma undergoing endoscopic hypophysectomy.\n* ASA physical status I and II.\n* Age above 21, below 45 years.\n* Male or female\n\nExclusion Criteria:\n\n* Any patient below 21 years or above 45 years.\n* Patients suffering from any of the following conditions:\n\n  * Disturbed conscious level.\n  * Coagulation abnormalities.\n  * Poorly controlled blood pressure and\u002For heart rate.\n  * Increased intracranial tension.\n  * Liver and kidney disorders.\n* Patients on anticoagulants and\u002For NSAIDS (non-steroidal anti- inflammatory drugs\n* Patients addicted to drugs and\u002For alcohol.\n* Patients with disturbed conscious level at the end of the surgery, GCS \\>14","21 Years","45 Years",{"count":372,"type":21},54,[24],"Patients undergoing endoscopic surgeries for pituitary adenoma excision suffer from wide swings in blood pressure that might increase bleeding and interfere with the surgical field.\n\nLocal anethetic infiltration and regional nerve blocks have been used to provide better analgesia, control blood pressure and improve surgical field.\n\nLimited studies evaluated shenopalatine ganglion block in pituitary adenoma excision with promising outcomes. The proposed study will compare the efficacy of two local anesthetics, prilocaine and lidocaine, for spenopalatine ganglion block in patients undergoing endoscopic pituitary adenoma excision. Evaluating the control of the intraoperative blood pressure and analgesic sparing are the main objectives of the proposed study.",[376],"Blood Pressure Control",[378,379,380,381],"Sphenopalatine ganglion block","Prilocaine","lidocaine","endoscopic hypophysectomy","2025-11-30",{"date":384,"type":36},"2025-12-05",{"date":386,"type":21},"2025-12-01",{"date":388,"type":21},"2026-02",{"name":42,"class":43},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":44},"100582346","phase-3-the-effect-of-discontinuation-of-renin-angiotensin-system-inhibitors-on-the-perioperative-myocardial-injury-in-adult-patients-undergoing-colorectal-cancer-surgery-100582346","NCT06862115","The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery","The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery: a Randomized Controlled Non Inferiority Study.","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both sexes\n* ASA 2-3\n* Chronic hypertensive patients (\\> 3 months before surgery) controlled on ACEIs or ARBs or combination therapy containing one of the RAS inhibitors.\n* Scheduled for major abdominal cancer surgery (surgery with an expected duration of \\> 2 h from the surgical incision and a postoperative hospital stay of least three days).\n\nExclusion Criteria:\n\n* Patient refusal.\n* Recent myocardial infarction (within 3 months).\n* Any condition, which in the opinion of the treating clinician, would result in the patient being harmed by the cessation of the ACE-I and\u002For ARB therapy.\n* Emergency surgery","70 Years",{"count":399,"type":21},156,[401],"PHASE3","The aim of this study is to estimate the effect of discontinuation of RAS inhibitors on myocardial injury in cancer patients undergoing major abdominal surgeries.",[404,405,406],"Myocardium; Injury","Perioperative\u002FPostoperative Complications","Angiotensin-Converting-Enzyme Inhibitor","2025-11-16",{"date":409,"type":36},"2025-11-18",{"date":411,"type":36},"2025-03-01",{"date":225,"type":21},{"name":42,"class":43},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":158,"minAge":421,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":4},"100601677","erector-spinae-plane-block-versus-iliohypogastricilioinguinal-nerve-block-for-post-hysterctomy-pain-relief-100601677","NCT07113600","Erector Spinae Plane Block Versus Iliohypogastric\u002FIlioinguinal Nerve Block for Post-Hysterctomy Pain Relief","A Randomized Comparative Study Between Ultrasound Guided Erector Spinae Plane Block and Ultrasound Guided Iliohypogastric\u002F Ilioinguinal Nerve Block for Postoperative Pain Relief in Female Patients Undergoing Open Hysterectomy","Inclusion Criteria:\n\n* Adult female patients above the age of 35 years.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n\nExclusion Criteria:\n\n* Patient refusal.\n* History of allergy or intolerance to study medications.\n* Chronic opioid use (\\>3 months).\n* Severe renal or hepatic impairment.\n* Patients with coagulopathy disorders.\n* Infection at injection sites.","35 Years",{"count":87,"type":21},[24],"The goal of this clinical trial is to compare the degree of pain relief between two techniques of regional anesthesia given to ladies undergoing hysterectomy under general anesthesia.\n\nOne group of patients will have a local anesthetic injected between muscle layers in their back (ultrasound guided Erector Spinae plane Block).\n\nThe other group will have a local anesthetic injected around specific nerves in their abdomen (ultrasound guided Ilio-hypogastric \u002F ilio-inguinal nerve block ).\n\nResearchers will compare the duration of postoperative pain relief , the degree of pain relief and any possible side effects of either techniques.",[426],"Postoperative Pain, Acute",[428,429,430,431,432,433,434],"Humans","Female","Anesthesia, Conduction","Ultrasonography","Nerve Block","Pain, Postoperative","Ultrasonography, Interventional","2025-08-02",{"date":437,"type":36},"2025-08-11",{"date":439,"type":21},"2025-08",{"date":441,"type":21},"2025-10",{"name":42,"class":43},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":397,"enrollmentInfo":449,"targetDuration":4,"studyType":22,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":44},"100595876","exploring-the-efficacy-of-single-stage-stapled-conversion-of-gastric-bypass-to-sleeve-gastrectomy-more-leak-100595876","NCT07038148","Exploring the Efficacy of Single-stage Stapled Conversion of Gastric Bypass to Sleeve Gastrectomy, More Leak?","Inclusion Criteria:\n\n* Age between 18-70\n* Adult patients undergoing single-stage laparoscopic stapled conversion of gastric bypass to sleeve gastrectomy.\n* Patients accept to sign an informed consent and will commit to follow-up.\n\nExclusion Criteria:\n\n* Patients with reversal gastric bypass to normal anatomy.\n* Patient with uncontrolled systemic disease.\n* Patients with active psychological disorders.\n* Patients with active substance abuse.\n* Patients with intra-operative technical difficulties hindering the conversion of gastric bypass to sleeve gastrectomy.\n* Patients refusing to sign an informed consent.",{"count":450,"type":21},11,[24],"Laparoscopic gastric bypass - including both Roux-en-Y gastric bypass (RYGB) and one anastomosis gastric bypass (OAGB) - is one of the most frequently performed procedures. However, as the number of gastric bypass surgeries increases, complications are being reported more often. While most post-bypass complications can be managed non-surgically, a small number of persistent cases may require a reversal to normal anatomy or conversion to another procedure.\n\nMany patients who experience severe complications from gastric bypass are reluctant to undergo a reversal to normal anatomy due to fears of regaining weight. As a result, converting to another type of surgery becomes a more logical alternative.\n\nComplications requiring conversion are numerous and negatively affect the quality of life, such as retrograde intussusception, weight regain, intractable dumping syndrome, and nutritional deficiencies. The high cost of obligatory postoperative vitamins is a potential cause of conversion especially in low-income countries.\n\nThe conversion procedure is technically demanding and has a relatively higher rate of postoperative complications, making it less commonly performed. Additionally, limited data is available regarding the procedure and its long-term outcomes, making it an unexplored sea of hope for people who wish to manage intractable complications of gastric bypass and maintain weight loss.",[454],"the Focus of the Study is to Assees Efficacy of Stapled Revision of Gastric Bypass to Sleeve Gastrectomy","2025-06-17",{"date":457,"type":36},"2025-06-26",{"date":459,"type":36},"2025-01-25",{"date":461,"type":21},"2026-01-30",{"name":42,"class":43},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":470,"targetDuration":4,"studyType":22,"phases":471,"briefSummary":472,"conditions":473,"keywords":474,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":44},"100578354","a-comparison-between-the-efficacy-of-modified-thoracoabdominal-plane-block-via-perichondral-approach-m-tapa-and-external-oblique-intercostal-plane-block-eoipb-in-patients-undergoing-laparoscopic-cholecystectomy-surgeries-lc-100578354","NCT06810206","A Comparison Between The Efficacy of Modified Thoracoabdominal Plane Block Via Perichondral Approach (M-TAPA) And External Oblique Intercostal Plane Block (EOIPB) in Patients Undergoing Laparoscopic Cholecystectomy Surgeries (LC)","A Comparison Between The Efficacy of Modified Thoracoabdominal Plane Block Via Perichondral Approach (M-TAPA) And External Oblique Intercostal Plane Block (EOIPB) in Patients Undergoing Laparoscopic Cholecystectomy Surgeries (LC): A Double-Blinded Randomized Comparative Study.","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Scheduled for Laparoscopic cholecystectomy surgery\n* ASA (American Society of Anaesthesiologists) physical status I-II\n\nExclusion Criteria:\n\n* Known allergy to local anaesthetics\n* Coagulopathy or anticoagulant use\n* Infection at the site of block\n* Chronic pain conditions\n* Advanced liver or kidney failure\n* History of abdominal surgery or trauma\n* Alcohol or drug use\n* Refusal to participate\n* Chronic opioid consumption\n* Use of painkillers in the preoperative 24hours\n* Conversion to open surgery\n* Body mass index ( BMI ) \\> 35",{"count":87,"type":21},[24],"Because laparoscopic procedures have a number of benefits over open procedures, they have completely changed the surgical industry.(1) Laparoscopic cholecystectomy (LC) is a minimally invasive technique that usually yields less discomfort following surgery, shorter hospital stays, and quicker patient recovery, plus it's an economical operation. Nevertheless, it results in moderate to severe pain.(2).By using regional anesthesia techniques to effectively control pain and lessen the requirement for opioid analgesics, ERAS implementation has demonstrated significant decreases in opioid usage and improved overall patient outcomes (3). (4) To minimize the need for opioids, opioid sparing anesthesia employs a multimodal strategy that includes nonsteroidal anti-inflammatory medications, paracetamol, local anesthetics (LA), and, if feasible, regional anesthetic techniques and regional analgesia. (5) With fewer systemic side effects, regional anesthetic techniques-like nerve blocks-offer tailored pain treatment. The best regional pain management strategy for LC surgery is still unknown, though.(4) Modified Thoracoabdominal Nerves Block Through Perichondral Approach (M-TAPA) Block is a new technique defined as a modification of TAPA Block in which local anaesthetics are administered only to the underside of the perichondral surface, creating a sensory block between T5-T12 dermatomes. While the external oblique intercostal plane (EOIPB) block provides blockade of the lateral and anterior cutaneous branches of the intercostal nerves from T6\u002F7 to T10\u002F11.This study aims to compare the efficacy of both MTAPA and EOIPB in patients undergoing LC surgery .",[142],[475],"postoperative pain","2025-02-15",{"date":478,"type":36},"2025-02-19",{"date":480,"type":21},"2025-03",{"date":482,"type":21},"2026-01",{"name":42,"class":43},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":235,"maxAge":397,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":507},"100569625","small-intestine-length-measurement-using-3d-ct-volumetry-and-in-vivo-measurement-using-pre-marked-graspers-in-revisional-bariatric-surgeries-a-comparative-study-100569625","NCT06696677","Small Intestine Length Measurement Using 3D CT Volumetry and in Vivo Measurement Using Pre-marked Graspers in Revisional Bariatric Surgeries. A Comparative Study","Inclusion Criteria:\n\n* Patients who are candidates for revisional bariatric surgery\n* Patients consenting to participate in the study.\n\nExclusion Criteria:\n\n* Patients with severe adhesions where measuring the small bowel may expose them to unnecessary injuries.\n* Patients refusing to participate in the study.\n* Patient refusing CT scan to be done pre-operatively.",{"count":491,"type":21},30,[24],"Measuring bowel length during hypo-absorptive surgeries like Roux-en-Y gastric bypass (RYGB) and Single Anastomosis Duodeno-ileal Sleeve (SADI-s) is controversial and usually abandoned due to the high risk of intestinal injury. However, some surgeons, especially in revisional surgery, prefer to count the whole bowel length to avoid leaving very short segments and severe malnutrition afterwards.\n\n3D reconstructed CT scan can be useful in such conditions, avoiding the risk of intestinal injury, but accurate measures might be doubtful.",[495],"Small Intestine Length",[497,498,499],"Small bowel Length","reconstructed 3D CT scan","Revisions bariatric Surgery",{"date":501,"type":36},"2025-01-28",{"date":503,"type":21},"2025-01-26",{"date":505,"type":21},"2025-07-31",{"name":42,"class":43},2,{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":109,"minAge":370,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":4},"100574375","bipolar-turp-versus-bipolar-enucleation-for-bph-management-100574375","NCT06758466","Bipolar TURP Versus Bipolar Enucleation for BPH Management","A Prospective Randomized Controlled Trial Comparing Bipolar TURP and Bipolar Enucleation of the Prostate for Benign Prostatic Hyperplasia (BPH) With Prostate Volumes Between 30-80 Grams","Inclusion Criteria:\n\n* Male patients aged 45-80 years diagnosed with symptomatic BPH.\n* Prostate volume between 30-80 grams as determined by transrectal ultrasound (TRUS) performed within 4 weeks before randomization.\n* Moderate to severe LUTS with an IPSS of ≥ 8.\n* Failure of medical management.\n* Patients able to provide written informed consent.\n\nExclusion Criteria:\n\n* History of prostate cancer.\n* History of previous prostate surgery (including any procedure for BPH or prostate cancer).\n* History of urethral stricture or bladder neck contracture.\n* Neurogenic bladder dysfunction.\n* Significant coagulopathy.\n* Uncontrolled urinary tract infection.\n* Patient on anticoagulant medication.","80 Years",{"count":517,"type":21},180,[24],"To compare the surgical outcomes at 12 months post-surgery between Bipolar TURP and BipoLEP in men with BPH and prostate volumes between 30-80 grams.",[521],"Benign Prostatic Hyperplasia",[523],"BPH - Bipolar- TURP - Enucleation","2025-01-02",{"date":526,"type":36},"2025-01-03",{"date":528,"type":21},"2025-01-15",{"date":530,"type":21},"2028-03-15",{"name":42,"class":43},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":109,"minAge":18,"maxAge":286,"enrollmentInfo":539,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":544,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":44},"100559010","efficacy-of-stromal-vascular-fraction-versus-platelet-rich-plasma-in-treatment-of-androgenitic-alopecia-100559010","NCT06558565","Efficacy of Stromal Vascular Fraction Versus Platelet Rich Plasma in Treatment of Androgenitic Alopecia","Efficacy of Stromal Vascular Fraction Versus Platelet Rich Plasma in Treatment of Androgenitic Alopecia:Randomized Clinical Trial","Inclusion Criteria:\n\n* 18 years or older.\n* Hamilton score I to VI in male patients.\n\nExclusion Criteria:\n\n* Patients with active infection, malignancy, autoimmune disease, and on current anticoagulant therapy.\n* Patient on chemotherapy during the last 5 years.\n* patients on topical or systemic treatment of AGA",{"count":540,"type":21},20,[24],"The goal of this randomized controlled clinical trial is to test the efficacy \\& safety of stromal vascular fraction in treatment of AGA \\& compare it to PRP The main questions it aims to answer are:\n\n* efficacy \\& safety of SVF for treatment of AGA patients\n* comparing it to PRP in treatment of AGA Participants will receive a single session of SVF in one half of the scalp \\& a single session of PRP in the other half.",[115],[545],"stromal vascular fraction - PRP- androgenetic alopecia","2024-08-14",{"date":548,"type":36},"2024-08-16",{"date":550,"type":21},"2024-08-30",{"date":552,"type":21},"2025-04-01",{"name":42,"class":43},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":574,"locationsCount":44},"100558305","topo-pachymetric-customized-accelerated-epi-on-vs-accelerated-epi-off-corneal-cross-linking-in-keratoconus-management-100558305","NCT06549387","Topo-Pachymetric Customized Accelerated Epi-On Vs Accelerated Epi-Off Corneal Cross Linking in Keratoconus Management","Topo-Pachymetric Customized Accelerated Epithelium-On Versus Standard Accelerated Epithelium-Off Corneal Collagen Cross Linking in the Management of Keratoconus","Inclusion Criteria:\n\n1. Age: 18 years or older\n2. Corrected distance visual acuity (CDVA) of ≥ 0.3 Snellen.\n3. Central corneal thickness (de-epithelialized) of ≥ 400 micron.\n4. Corneal endothelial count of ≥ 2000.\n\nExclusion Criteria:\n\n1. Previous eye surgery\n2. The presence of lesions other than keratoconus, central or paracentral scaring\n3. History of Cross linking\n4. History of viral keratitis\n5. Connective tissue diseases\n6. Pregnancy or lactation during the study.\n7. The presence of nystagmus",{"count":562,"type":21},55,[24],"The objective of this study is to compare the clinical effectiveness and safety of Topo-Pachymetric Customized Accelerated Epithelium-On (aCFXL) to Standard Accelerated Epithelium-Off (aCXL) Corneal Collagen Cross-Linking in the management of keratoconus. The study aims to evaluate visual and structural outcomes, to provide valuable insights into optimizing treatment strategies.",[566,567],"Amount of Corneal Flattening (Kmax Flattening)","Change in the Endothelial Cell Count","2024-08-09",{"date":570,"type":36},"2024-08-12",{"date":572,"type":21},"2024-08-15",{"date":334,"type":21},{"name":42,"class":43},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":286,"enrollmentInfo":582,"targetDuration":4,"studyType":22,"phases":583,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":4},"100553786","phase-4-dexmedetomidine-and-nalbuphine-as-analgesic-adjuvants-to-bupivacaine-in-superficial-cervical-block-100553786","NCT06490614","Dexmedetomidine and Nalbuphine as Analgesic Adjuvants to Bupivacaine in Superficial Cervical Block.","Comparative Study Between Dexmedetomidine and Nalbuphine as Analgesic Adjuvants to Bupivacaine in Superficial Cervical Block for Patients Undergoing Anterior Cervical Discectomy and Fusion (ACDF) Surgery A Double Blinded Randomized Trial","Inclusion Criteria:\n\n* Physical status ASA I and ASA ll.\n* Both males and females\n* Age 21- 60 years.\n* Patients undergoing elective anterior cervical discectomy and fusion for 1 or 2 levels.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients undergoing anterior cervical vertebrectomy and reconstruction.\n* Patients with a history of allergy to local anesthetics or any used drugs in study.\n* Infection at the site of the block.\n* Patients with multiple cervical spine traumas.\n* Patients having surgery for malignant tumors.\n* Pre-existing peripheral neuropathies.\n* Pregnant female.\n* Patients with uncontrolled hypertension or cardiac problems as (heart block, sick sinus syndrome and ischemic heart disease).\n* Patients with coagulopathy (INR\\>1.5).\n* Patients with failed block.",{"count":491,"type":21},[89],"Anterior cervical discectomy and fusion (ACDF) nowadays is considered a common procedure.postoperative pain can hinder recovery and prolong hospital stay. The superficial cervical plexus block (SCPB) is a safe and simple technique that had been found to allow good pain relief in neck surgeries. The main drawback of SCPB was short duration, so adjuvants as dexmedetomidine and opioids has been used to increase analgesic duration and decrease the use of opioids.\n\nThe current study will compare the efficacy of dexmedetomidine and nalbuphine as adjuvants to bupivacaine in SCPB in anterior cervical fusion surgeries.",[586],"Anterior Cervical Discectomy and Fusion (ACDF)","2024-07-05",{"date":589,"type":36},"2024-07-08",{"date":591,"type":21},"2024-07",{"date":593,"type":21},"2024-11",{"name":42,"class":43},{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":601,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":44},"100553848","is-there-a-role-for-hip-arthroscopy-in-patients-with-femoral-head-fractures-100553848","NCT06491420","Is There a Role for Hip Arthroscopy in Patients With Femoral Head Fractures?","Inclusion Criteria:\n\n* Patients with pipkin 1 fractures\n\nExclusion Criteria:\n\n* any associated pelvic fractures\n* severe medical conditions that prevent the patient from undergoing surgery\n* delayed presentation after 2 weeks from initial fracture date","55 Years",{"count":603,"type":21},5,[24],"Femoral head fractures, often caused by high-energy trauma, pose significant challenges due to complications like avascular necrosis, post-traumatic osteoarthritis, and sciatic nerve damage. While traditionally treated with open reduction and internal fixation (ORIF) or total hip replacement (THR), hip arthroscopy has emerged as a minimally invasive alternative that reduces surgical trauma, offers direct fracture visualization and manipulation, and may result in shorter recovery times and fewer complications.",[607,608],"Femur Head Fracture","Arthroscopy","2024-07-01",{"date":611,"type":36},"2024-07-09",{"date":613,"type":36},"2022-01-01",{"date":615,"type":21},"2024-12-01",{"name":42,"class":43},""]